IMUX
Immunic IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$136.62M
P/E Ratio
—
EPS
$-6.20
Beta
1.37
52W High
$15.10
52W Low
$5.06
50-Day MA
$11.01
200-Day MA
$8.62
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Immunic Inc
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-103.06M |
| Operating Margin | 0.00% |
| Return on Equity | -1653.00% |
| Return on Assets | -198.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.06 |
| Price-to-Book | 12.72 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $13.62M |
| Float | $10.71M |
| % Insiders | 0.97% |
| % Institutions | 46.26% |
Historical Volatility
HV 10-Day
110.66%
HV 20-Day
95.37%
HV 30-Day
100.33%
HV 60-Day
109.92%
HV Rank
66.3%
Volatility is currently expanding
Analyst Ratings
Consensus ($53.57 target)
9
BuyData last updated: 4/30/2026